First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05156866 |
Recruitment Status :
Recruiting
First Posted : December 14, 2021
Last Update Posted : December 12, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Advanced Solid Tumor Gastric Cancer Pancreas Cancer Gastroesophageal Junction Adenocarcinoma | Drug: TORL-2-307-ADC | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 70 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1, First in Human, Dose-Escalation Study of TORL-2-307-ADC in Participants With Advanced Cancer |
Actual Study Start Date : | February 2, 2022 |
Estimated Primary Completion Date : | January 15, 2025 |
Estimated Study Completion Date : | January 15, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Monotherapy Dose Dose Finding - Part 1
TORL-2-307-ADC
|
Drug: TORL-2-307-ADC
antibody drug conjugate |
Experimental: Expansion as Monotherapy - Part 2
TORL-2-307-ADC
|
Drug: TORL-2-307-ADC
antibody drug conjugate |
- Incidence and severity of adverse events and serious adverse events [ Time Frame: up to 2 years ]Incidence and severity of adverse events, serious adverse events, according to NCI-CTCAE Version 5.0
- Maximum Tolerated Dose (MTD) [ Time Frame: 28 Days ]Highest administered dose with < 33% participants experiencing dose limiting toxicity (DLT) in the first 6 DLT evaluable participants
- Recommended Phase 2 Dose (RP2D) [ Time Frame: up to 2 years ]Based on the maximum tolerated dose, cumulative safety, and pharmacokinetic data
- Objective Response Rate (ORR) [ Time Frame: up to 2 years ]Percentage of participants with best response of complete response (CR) or partial response (PR) according to RECIST 1.1
- Duration of Response (DOR) [ Time Frame: up to 2 years ]Time from CR or PR to objective disease progression or death to any cause
- Progression Free Survival (PFS) [ Time Frame: up to 2 years ]PFS is defined as the time from the start of the treatment until objective disease progression or death from any cause
- Time to Response (TTR) [ Time Frame: up to 2 years ]Time from start of treatment to complete response or partial response
- 1 Year Overall Survival (1YOS) [ Time Frame: 1 year ]Proportion of participants alive at 1 year from the start of treatment to death from any cause
- 2 Year Overall Survival (2YOS) [ Time Frame: 2 years ]Proportion of participants alive at 2 years from the start of treatment to death from any cause
- Number of anti-drug antibody (ADA) Positive Participants [ Time Frame: up to 2 years ]Immunogenicity will be measured by the number of participants that are ADA positive.
- Maximum Serum Concentration of TORL-2-307-ADC (Cmax) [ Time Frame: 21 days ]PK assessment
- Minimum Serum Concentration of TORL-2-307-ADC (Cmin) [ Time Frame: 21 days ]PK assessment
- Maximum Serum Concentration of TORL-2-307-ADC at Steady State (Cmax,ss) [ Time Frame: 63 days ]PK assessment
- Minimum Serum Concentration of TORL-2-307-ADC at Steady State (Cmin,ss) [ Time Frame: 63 days ]PK assessment
- Time of Maximum Serum Concentration of TORL-2-307-ADC (Tmax) [ Time Frame: 21 days ]PK assessment
- Time of Minimum Serum Concentration of TORL-2-307-ADC (Tmin) [ Time Frame: 21 days ]PK Assessment
- Time of Minimum Serum Concentration of TORL-2-307-ADC at Steady State (Tmin,ss) [ Time Frame: 63 days ]PK Assessment
- Terminal Half-life (t1/2) of Serum TORL-2-307-ADC [ Time Frame: 63 days ]PK Assessment
- Area under the Serum Concentration-Time curve from the time of dosing to the last measurable concentration (AUClast) for TORL-1-23 [ Time Frame: 21 days ]PK Assessment
- Area under the Serum Concentration-Time curve from the time of dosing extrapolated to time infinity (AUCinf) for TORL-1-23 [ Time Frame: 63 days ]PK Assessment
- Apparent volume of distribution during the terminal phase (Vz) of TORL-2-307-ADC [ Time Frame: 63 days ]PK Assessment
- Clearance (CL) of TORL-2-307-ADC [ Time Frame: 63 days ]PK Assessment
- Accumulation ratio (Rac) of TORL-2-307-ADC [ Time Frame: 63 days ]PK Assessment
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Advanced solid tumor
- Measurable disease, per RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Adequate organ function
Exclusion Criteria:
- Has not recovered [recovery is defined as NCI CTCAE, version 5.0, grade ≤1] from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements
- Received prior chemotherapeutic, investigational, or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of TORL-2-307-MAB
- Progressive or symptomatic brain metastases
- Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection
- History of significant cardiac disease
- History of myelodysplastic syndrome (MDS) or AML
- History of another cancer within 3 years before Day 1 of study treatment, with the exception of basal or squamous cell carcinoma of the skin that has been definitively treated. A history of other malignancies with a low risk of recurrence, including appropriately treated ductal carcinoma in situ (DCIS) of the breast and prostate cancer with a Gleason score less than or equal to 6, are also not excluded
- If female, is pregnant or breastfeeding
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05156866
Contact: Stephen Letrent, PharmD, PhD | 858-342-6652 | stephen.letrent@torlbio.com |
United States, California | |
Providence St. Jude Medical Center | Recruiting |
Fullerton, California, United States, 92835 | |
Contact: David J Park, MD | |
UCLA - JCCC Clinical Research Unit | Recruiting |
Los Angeles, California, United States, 90095 | |
Contact: Zev Wainberg, MD 310-586-2094 | |
Torrance Memorial Medical | Recruiting |
Torrance, California, United States, 90505 | |
Contact: Hugo Hool, MD | |
United States, Indiana | |
Fort Wayne Medical Oncology and Hematology | Recruiting |
Fort Wayne, Indiana, United States, 46804 | |
Contact: Sunil Babu, MD | |
Korea, Republic of | |
Seoul National University Hospital | Recruiting |
Seoul, Korea, Republic of, 03080 | |
Contact: Tae Yong Kim | |
Severance Hospital, Yonsei University Health System | Recruiting |
Seoul, Korea, Republic of, 03722 | |
Contact: Sun Young Rha | |
Seoul National University Bundang Hospital | Recruiting |
Seoul, Korea, Republic of, 13620 | |
Contact: Keun Wook Lee |
Study Director: | Stephen Letrent, PharmD, PhD | TORL Biotherapeutics, LLC |
Responsible Party: | TORL Biotherapeutics, LLC |
ClinicalTrials.gov Identifier: | NCT05156866 |
Other Study ID Numbers: |
TORL2307ADC-001 |
First Posted: | December 14, 2021 Key Record Dates |
Last Update Posted: | December 12, 2023 |
Last Verified: | December 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
claudin18.2 |
Pancreatic Neoplasms Neoplasms Digestive System Neoplasms Neoplasms by Site |
Digestive System Diseases Endocrine Gland Neoplasms Pancreatic Diseases Endocrine System Diseases |